Overview Of Metastatic Melanoma - Pipeline Analysis, H1 2017

Researchmoz added Most up-to-date research on "Overview Of Metastatic Melanoma - Pipeline Analysis, H1 2017" to its huge collection of research reports.

Global Markets Directs, Metastatic Melanoma Pipeline Review, H1 2015, provides an overview of the Metastatic Melanomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

• The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=245098

• The report summarizes all the dormant and discontinued pipeline projects 
• A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=245098

Competitive Landscape, Technology And Pipeline Analysis Of Natural Killer Cells During 2017

Researchmoz added Most up-to-date research on "Competitive Landscape, Technology And Pipeline Analysis Of Natural Killer Cells During 2017" to its huge collection of research reports.

DelveInsights, Natural Killer Cells- Competitive Landscape, Technology and Pipeline Analysis, 2016, report provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Natural Killer Cells.

This report provides information on the therapeutic development based on the Natural Killer Cells dealing with all the pipeline drugs, comparative analysis of Natural Killer Cellsat various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companys information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Note: This report will be delivered to the client in 48 hours

Reports Highlights

Natural killer cell Therapy Pipeline scenario
Collaborations & partnering deals
Current Prominent Research Areas and Key Players
Pipeline product profiles Natural killer cell Technologies and Targeted Antigens
Licensing opportunities
Market Drivers and Barriers

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=745910

Table of Contents
1 Executive Summary Snapshot Report
2 Executive Summary
3 Natural Killer Cells Overview
4 Analysis of NK cells receptors
NK cells receptors and shares
CAR-expressing NK-92 associated targets and Indications
Targets of NK cells and Analysis
Pipeline products under development by the company
NK Cells Therapy Collaborations and Deal Year
NK Cells Therapy Collaborations and Deal value
Companies Licensing Agreement for NK cells
Financing details of NK cells
Companies received Grants for NK cells
Designation
Institutes involved in NK cells
NK cells Technologies
Clinical trials & Completion Year
Phase III Drugs
Phase II Drugs
Phase I Drugs
Recent Trends in NK Cells Therapy
Leading Companies and their shares in Natural Killer cells Therapy
Market Drivers
Market Barriers
5 SWOT Analysis
6 Pipeline Therapeutics
7 Therapeutics under Development by Companies
8 Last Stage Products (Phase III)
Comparative Analysis
10 Mid Stage Products (Phase II)
Comparative Analysis
19 Early Stage Products (Phase I)
Comparative Analysis
42 Pre-Clinical and Discovery Products
Comparative Analysis
50 Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=745910

2017 - 2020, Pipeline Analysis of Global Hospital Acquired Pneumonia Drugs Market: Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix

ResearchMoz presents this most up-to-date research on "2017 - 2020, Pipeline Analysis of Global Hospital Acquired Pneumonia Drugs Market: Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix".

Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.

Phase III candidates include tedizolid phosphate, ceftolozane/tazobactam, ceftazidime/avibactam, amikacin inhale, plazomicin and synflorix vaccine. Market for each of the investigational drugs is estimated based on current anti-microbial efficiency, historic market trend and patents of drugs from similar class, manufacturing and marketing licenses, along with competition from commercialized and pipeline drugs. Hospital acquired pneumonia drugs market for phase III candidates has been estimated from the expected year of launch till 2020. The hospital acquired pneumonia drugs market report also gives a brief review of the various drugs commercially available for treating hospital acquired pneumonia. Historic market revenue of these drugs from 2011 to 2013 has also been included. Market forecast mainly rests on a detailed event impact analysis, which considers historic as well as anticipated events which impact the market in varying degrees. 

Global market for hospital acquired pneumonia drugs is mainly driven by the increasing prevalence of nosocomial infections across the globe. To illustrate this fact, the report includes a statistical comparison of the prevalence of nosocomial infections in various developed and developing countries. Geographical trend of hospital acquired pneumonia drugs market, is explains with a brief regulatory approval process, along with expected time frame for drug launch in various countries. These trends have been explained for geographical regions including North America, Europe, Asia Pacific and Rest of the World.

To gain a complete market understanding, Porters Five Force’s analysis, and value chain analysis has also been included in the hospital acquired pneumonia drugs market report. The report also explains key market drivers, restraints, opportunities in the hospital acquired pneumonia drugs market. Diagnosis, treatment, and epidemiology of hospital acquired pneumonia gives a clinical overview of the disease and current modes of disease management. Relevant recommendations have been suggested for designing successful market strategies for competing in the market. 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=194543

Hospital acquired pneumonia drugs market report also includes company profiles of key market players. These include Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Ltd., Sanofi, GlaxoSmithKline, Inc., and Valneva SE. All of these players are profiled considering company overview, financial overview, product portfolio, business strategies, and recent developments.   

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players’ product literature, annual reports, and press releases supports the market forecast analysis. The 74 page report explains various market dynamics in 4 tables and 17 figures and charts.

Table of Contents

Chapter 1 Introduction

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.3.1 Secondary Research

1.3.2 Primary Research

1.4 List of Abbreviations

1.5 Assumptions

Chapter 2 Executive Summary

2.1.1 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)

Chapter 3 Market overview

3.1 Introduction

3.1.1 Types of Nosocomial Pneumonia

3.1.1.1 Bacterial pneumonia

3.1.1.2 Viral pneumonia

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=194543

Current And Future Market For Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017

ResearchMoz presents this most up-to-date research on "Current And Future Market For Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017".

DelveInsights, Immune Checkpoints Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Immune Checkpoints Activators. 

This report provides information on the therapeutic development based on Immune Checkpoints Activators mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. 

Report contains the development and sale activities for marketed drugs. DelveInsights Report also assesses the Immune Checkpoints Activators therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products. 

Scope 
The report provides competitive pipeline landscape of Immune Checkpoints Activators
The report provides the marketed drugs information including its sales, development activities and details of patent expiry
The report provides the insight of current and future market for Immune Checkpoints Activators
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=964544

The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
The report also gives the information of dormant pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy
Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
Complete MOA intelligence and complete understanding over therapeutics development for Immune Checkpoints Activators
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding Immune Checkpoints Activators pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=964544

Refractive Surgery Devices Global Market - Pipeline Analysis, Opportunity Assessment and Forecasts to 2018

ResearchMoz presents this most up-to-date research on "Refractive Surgery Devices Global Market - Pipeline Analysis, Opportunity Assessment and Forecasts to 2018".

GlobalData’s new report, “Refractive Surgery Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016” provides key data, information and analysis on the global refractive surgery devices market. The report provides market landscape, competitive landscape and market trends information the refractive surgery devices market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

Scope

• Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
• Key segments covered include ophthalmic lasers (Excimer Laser, Femtosecond Laser, YAG Laser) and Microkeratome.
• Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2009.
• Qualitative analysis of key market trends, market drivers, and restraints by each category within refractive surgery devices market.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=41736

• The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
• Key players covered include Abbott Medical Optics, Bausch & Lomb, Alcon, Carl Zeiss, and NIDEK.

Reasons to buy

• Develop business strategies by understanding the trends and developments that are driving the refractive surgery devices market globally.
• Design and develop your product development, marketing and sales strategies.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• What’s the next big thing in the refractive surgery devices market landscape? - Identify, understand and capitalize.
• Make more informed business decisions from the insightful and in-depth analysis of the global refractive surgery devices market and the factors shaping it.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=41736